Loading...
XJPX
4539
Market cap37mUSD
Jul 10, Last price  
1,692.00JPY
1D
1.38%
1Q
-1.51%
Jan 2017
-68.95%
Name

Nippon Chemiphar Co Ltd

Chart & Performance

D1W1MN
XJPX:4539 chart
P/E
30.98
P/S
0.19
EPS
54.62
Div Yield, %
3.00%
Shrs. gr., 5y
0.10%
Rev. gr., 5y
0.96%
Revenues
33.09b
+1.60%
20,918,000,00022,307,000,00023,982,000,00027,361,000,00028,513,000,00031,944,000,00031,893,000,00035,118,000,00035,602,000,00035,688,000,00035,331,000,00034,182,000,00031,757,000,00031,541,000,00032,506,000,00031,559,000,00030,748,000,00032,570,000,00033,090,000,000
Net income
198m
-32.65%
390,000,000168,000,000270,000,000573,000,0001,439,000,0002,125,000,0001,887,000,0001,899,000,0001,961,000,0002,054,000,0001,160,000,000881,000,000436,000,000495,000,000700,000,000339,000,000-180,000,000294,000,000198,000,000
CFO
620m
P
-82,000,000-3,261,000,0001,889,000,0002,748,000,0001,753,000,0001,912,000,0001,892,000,0002,438,000,0002,450,000,0002,737,000,0003,188,000,0002,196,000,0001,394,000,0001,503,000,0001,801,000,000-916,000,000296,000,000-265,000,000620,000,000
Dividend
Mar 30, 202650 JPY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Nippon Chemiphar Co., Ltd., alongside its subsidiaries, is a global pharmaceutical entity engaged in the research, production, marketing, and sale of ethical drugs and diagnostic agents. Its diagnostic product lineup features the IgE NC kit, which measures overall IgE levels and identifies 57 specific allergens, as well as the DP3000 device for accurate allergen-specific IgE testing. The company's development pipeline includes NC-2400, a PPAR-delta agonist; NC-2500, a novel xanthine oxidoreductase inhibitor targeting hyperuricemia and gout; and NC-2600, a P2X4 receptor antagonist for neuropathic pain. Additionally, it is advancing NC-2700, a new urate transporter 1 inhibitor designed to enhance urinary urate excretion, and NC-2800, a delta opioid receptor agonist for treating depression and anxiety. Its commercialized pharmaceuticals comprise Uralyt-U (an alkalization therapeutic), Soleton (an analgesic and anti-inflammatory medication), and Calvan (a drug for hypertension). Beyond pharmaceuticals, Nippon Chemiphar offers a variety of quasi-drugs, nutritional supplements, health foods, cosmetics, and different types of creams. Its generic medications reach hospitals and pharmacies via wholesale distributors. Founded in Tokyo, Japan, in 1950, the company was initially known as Hitachi Chemical Co., Ltd., changing its name to Nippon Chemiphar Co., Ltd. in 1970.
IPO date
Oct 01, 1971
Employees
872
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT